Literature DB >> 24450984

Contemporary generic market in Japan - key conditions to successful evolution.

Mihajlo B Jakovljevic1, Sanae Nakazono, Seiritsu Ogura.   

Abstract

The Japanese pharmaceutical market, the world's second largest, is traditionally renowned for the domination of patented drugs and the weakest generics share among major established economies. An in-depth observation of published evidence in Japanese/English language provided closer insight into current trends in Japanese domestic legislation and pharmaceutical market development. Recent governmental interventions have resulted in significant expansion of the generic medicines market size. Substantial savings due to generic substitution of patent-protected drugs have already been achieved and are likely to increase in future. Nationwide population aging threatening sustainable healthcare funding is contributing to the relevance of generic policy success. Serious long-term challenges to the modest Japanese generic manufacturing capacities will be posed by foreign pharmaceutical industries particularly the ones based in emerging BRIC economies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24450984     DOI: 10.1586/14737167.2014.881254

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  16 in total

1.  Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.

Authors:  François Bocquet; Anaïs Loubière; Isabelle Fusier; Anne-Laure Cordonnier; Pascal Paubel
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

2.  Economic Impact of Leading Prosperity Diseases: COPD in South East Europe.

Authors:  Vojislav Cupurdija
Journal:  Front Public Health       Date:  2015-03-24

3.  Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan.

Authors:  Jörg Mahlich; Masamichi Nishi; Yoshimichi Saito
Journal:  Clinicoecon Outcomes Res       Date:  2015-05-22

Review 4.  Peculiarity of Pharmaceutical Marketing in Serbia.

Authors:  Veselin Dickov
Journal:  Front Public Health       Date:  2015-06-25

5.  Pharmaceutical Expenditure and Burden of Non-communicable Diseases in Serbia.

Authors:  Aleksandra Kovacevic; Nemanja Rancic; Zoran Segrt; Viktorija Dragojevic-Simic
Journal:  Front Pharmacol       Date:  2016-10-13       Impact factor: 5.810

6.  Global pharmaceutical regulation: the challenge of integration for developing states.

Authors:  Anthony Pezzola; Cassandra M Sweet
Journal:  Global Health       Date:  2016-12-20       Impact factor: 4.185

7.  The New and Old Europe: East-West Split in Pharmaceutical Spending.

Authors:  Mihajlo Jakovljevic; Marija Lazarevic; Olivera Milovanovic; Tatjana Kanjevac
Journal:  Front Pharmacol       Date:  2016-02-09       Impact factor: 5.810

8.  Commentary: Patient Cost Sharing and Medical Expenditures for the Elderly.

Authors:  Mihajlo Jakovljevic
Journal:  Front Pharmacol       Date:  2016-03-30       Impact factor: 5.810

9.  Sales promotion by wholesalers affects general practitioners' prescription behaviours in Japan.

Authors:  Hirohisa Shimura
Journal:  J Mark Access Health Policy       Date:  2018-01-18

10.  Editorial: Role of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies.

Authors:  Mihajlo Jakovljevic; Tetsuji Yamada
Journal:  Front Pharmacol       Date:  2017-09-21       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.